Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...
Ivonescimab combined with chemotherapy showed significant progression-free survival benefits in advanced squamous NSCLC patients, including both PD-L1-positive and PD-L1-negative populations. The ...
(Trinity Capital) with $50 million drawn down at closing, and access of up to an additional $80 million Cash and cash equivalents of $119.7 million, as of December 31, 2025, together with $93.5 ...
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced ...
After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...
Telisotuzumab vedotin-tllv is now approved for advanced non-squamous NSCLC with high c-Met overexpression after prior treatment. The drug targets c-MET expression, impacting approximately 25% of EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results